New paediatric influenza vaccination recommendations have been published by the US Centers for Disease Control and Prevention

2004 ◽  
Vol &NA; (1437) ◽  
pp. 4
Author(s):  
&NA;
Keyword(s):  
Influenza Vaccination ◽  
Disease Control ◽  
Vaccination Recommendations ◽  
The Us ◽  
Control And Prevention ◽  
Centers For Disease Control

scholarly journals Effectiveness of the US Centers for Disease Control and Prevention HEADS UP coaches’ online training as an educational intervention

2019 ◽  
Vol 78 (7) ◽  
pp. 784-797 ◽  
Author(s):  
Jill Daugherty ◽  
Lara DePadilla ◽  
Kelly Sarmiento
Keyword(s):  
Disease Control ◽  
Online Training ◽  
Return To Play ◽  
Rank Test ◽  
The Us ◽  
Post Test ◽  
Control And Prevention ◽  
Signed Rank Test ◽  
Centers For Disease Control ◽  
High Level

Background: Concussions are common among youth athletes. Responsibility for the recognition and management of concussion is often put on coaches. To equip coaches with appropriate knowledge and skills, the US Centers for Disease Control and Prevention (CDC) launched the HEADS UP: Concussion in Youth Sports online training. Objectives: To determine whether HEADS UP coaches’ training improves knowledge, attitudes and behavioural intentions. Methods: Knowledge questions were grouped into scales by level of difficulty. Differences between pre- and post-test scores were calculated based on the Wilcoxon Signed Rank Test Z-score and effect sizes were interpreted. Results: Coaches displayed a high level of knowledge in the pre-test. While lower difficulty questions did not show improvement from pre- to post-test, moderate and high difficulty questions did. Use of the training was associated with improved knowledge about symptom resolution, return-to-play recommendations and under-reporting of incidents of concussion. Coaches demonstrated improvement in five of the seven concussion-related attitude and behavioural intention items post training. Conclusion: HEADS UP training improved coaches’ knowledge on select topics and helped them feel more comfortable about responding to concussion among their athletes. This study provides insight into how to better focus future HEADS UP concussion health education efforts to fit coaches’ informational needs.

scholarly journals CDC Warns of Increased Ivermectin Overdoses

2021 ◽  
Vol 23 (2) ◽  
pp. 62-63
Author(s):  
Richard Robbins ◽  
Keyword(s):  
Disease Control ◽  
River Blindness ◽  
The Us ◽  
Control And Prevention ◽  
Centers For Disease Control ◽  
In Cells

No abstract available. Article truncated after 150 words. The US Centers for Disease Control and Prevention (CDC) is warning of an increase in cases of ivermectin overdose due to people self-prescribing the drug in an effort to prevent or treat COVID-19 (1). Ivermectin is used to treat river blindness and intestinal roundworm infection in humans and to de-worm pets and livestock. A study published earlier this year showed that ivermectin killed SARS-CoV-2 in cells in vitro. The authors proposed that the medication be investigated as a cheap and easily available treatment for COVID-19. However, subsequent studies have failed to find any benefit in humans (3). In a new communication to its Health Alert Network, the CDC says cases of overdose and misuse are rising (1). More than 88,000 prescriptions were written for the drug ivermectin in the week ending August 13, an increase of 2400% over the weekly average prior to the COVID-19 pandemic (Figure 1). Unfortunately, the …

scholarly journals EU financial accounts reports

10.5912/jcb96 ◽  
2004 ◽  
Vol 10 (4) ◽  
Author(s):  
Colin Aaronson
Keyword(s):  
Research And Development ◽  
Disease Control ◽  
Smallpox Vaccine ◽  
Biotechnology Company ◽  
Stages Of Development ◽  
The Third ◽  
The Us ◽  
Development Expenditure ◽  
Control And Prevention ◽  
Centers For Disease Control

Acambis is a profitable and cash-generative biotechnology company that is focused on building a substantial franchise in the vaccine space. Its results for the period have benefited significantly from its contract to supply 155 million doses of its ACAM2000 smallpox vaccine to the US Centers for Disease Control and Prevention (CDC). During the year ended 31st December, 2003, Acambis generated profit before taxation (before exceptional items) of £46.8m on sales of £169.1m compared with a profit of £9.6m on sales of £79.7m for the whole of 2002. The pre-tax profit for the year was £39.4m, after taking account of an exceptional cost of £7.4m following a settlement with BTG International Limited to discharge all rights and obligations under a technology licence agreement established in 1994. The profit was earned mainly in the third quarter, with £22.2m earned during the three months ended 30th September, 2003, the company having earned £20.6m for the six months ended 30th June, 2003. Research and development expenditure increased from £16.5m in 2002 to £19.1m in 2003, the result of the progression of the company's products to the later stages of development.

Sign in / Sign up

Export Citation Format

Share Document